1. Jemal A, Siegel R,Ward E et al. Cancer statistics. CA Cancer J Clin 2008; 58: 71–96.
2. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92–8.
3. Pfister DG, Johnson DH, Azzoli CG et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004; 22 (24): 330–59.
4. Socinski MA, Crowell R, Hensing TE et al. Treatment of non-small-cell lung cancer, stage IV: ACCP evidence-based clinical practice guidelines (2nd Edition). Chest 2007; 132 (3): S277–89.
5. Waters JS, O’Brien MER. The case for the introduction new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake if the findings of the National Institute of Clinical Excellence (NICE). Br J Cancer 2002; 87 (5): 481–90.
6. Ardizzoni A, Boni L, Tiseo M et al. Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small cell lung cancer: an individual patients data meta-analysis. J Natl Cancer Inst 2007; 99 (11): 847–57.
7. Hirsch FR, Spreafico A, Novello S et al. The prognostic and predictive role of histology in advanced non-small cell lung cancer. A literature review. J Thorac Oncol 2008; 3 (12): 1468–81.
8. Gabrielson E. Worldwide trends in lung cancer pathology. Respirology 2006; 11 (5): 533–8.
9. Shih C, Chen VJ, Gossetti LS et al. LY231514, a pirrolo[2,3-d]pyrimidine-based antifolate that inhibitsmultiple folate requiring enzymes. Cancer Res 1997; 57: 1116–23.
10. Schultz RM, Chen VJ, Bewley JR et al. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Sem Oncol 1999; 26 (6): 68–73.
11. Ceppi P, Volante M, Saviozzi S et al. Squamous cell carcinoma of the lungcompared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthetase. Cancer 2006; 107: 1589–96.
12. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636–44.
13. Hanna N, Shepherd FA, Fossella FV et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non small cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589–97.
14. Scagliotti G, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patientswith advanced-stage NSCLC. J Clin Oncol 2008; 26: 3543–51.
15. Niyikiza C, Baker SD, Seitz DE et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002; 1: 545–52.
16. Cullen MH, Zatloukal P, Sorenson S et al. A randomized phase III trial comparing standard and high dose pemetrexed as second-line treatment in patients with locally advanced or metastatic nonsmall cell lung cancer. Ann Oncol 2008; 19: 939–45.
17. Ohe Y, Ichinose Y, Nakagawa K et al. Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patientswith non-small cell lung cancer. Clin Cancer Res 2008; 14: 4206–12.
18. Scagliotti G, Hanna N, Fossella F et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009; 14: 253–63.
19. Peterson P, Park K, Fossella F et al. Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs. docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2007; 2 (4): S851 [abstract P2-328].
20. Smit EF, Burgers SA, Biesma B et al. Randomized phase II and pharmacogenetic study of pemetrexed compared with pemetrexed plus carboplatin in pretreated patients with advanced non-small cell lung cancer. J Clin Oncol 2009; 27: 2038–45.
21. Rusthoven JJ, Eisenhauer E, Butts C et al. Multitargeted antifolate LY2311514 as first line chemotherapy for patients with advanced non small cell lung cancer: a phase II study. J Clin Oncol 1999; 17: 1194–9.
22. Clarke SJ, Abratt R, Goedhals L et al. Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naive patients with advanced non small cell lung cancer. Ann Oncol 2002; 13: 737–41.
23. Gridelli C, Kaukel E, Gregorc V et al. Single-agent pemetrexed or sequential pemetrexed/gemcitabine as front-line treatment of advanced non-small cell lung cancer in elderly patients or patients ineligible for platinum-based chemotherapy: amulticenter, randomized, phase II trial. J Thorac Oncol 2007; 2: 221–9.
24. Monnerat C, Le Chevalier T, Kelly K et al. Phase II study of pemetrexed-gemcitabine combination in patients with advanced stage non-small cell lung cancer. Clin Cancer Res 2004; 10: 5439–46.
25. Ma CX, Nair S, Thomas S et al. Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. J Clin Oncol 2005; 23: 5929–37.
26. Treat J, Bonomi P, McCleod M et al. Administration ofpemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: a phase II trial. Lung Cancer 2006; 53: 77–83.
27. Ye Z, Treat JA. Meta-analysis of pemetrexed (P) plus gemcitabine (G) in first-line, advanced (adv) non-small cell lung cancer (NSCLC). J Clin Oncol 2007; 25 (18S): 685s [abstract 18015].
28. Clarke SJ, Boyer MJ, Millward M et al. A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer. Lung Cancer 2005; 49: 401–12.
29. Shepherd FA, Dancey J, Arnold A et al. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced non-small cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. Cancer 2001; 92 (3): 595–600.
30. Manegold C, Gatzemeier U, von Pawel J et al. Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multitarget Phase II trial. Ann Oncol 2000; 11 (4): 435–40.
31. Scagliotti GV, Kortsik C, Dark GG et al. Pemetrexed combined with oxaliplatin or carboplatin as front-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, Phase II trial. Clin Cancer Res 2005; 11 (2): 690–6.
32. Zinner RG, Fossella FV, Gladish GW et al. Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced non-small cell lung cancetr. Cancert 2005; 104 (11): 2449–56.
33. Orlando M, Lee JS, Yang C et al. Efficacy of pemetrexed-cisplatin (PC) in East Asian patients (pts): subgroup analysis of a phase III study comparing PC versus gemcitabine-cisplatin (GC) in first-line treatment of advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2009; 27 (15S): 418s [abstract 8045].
34. Grossi F, Aita M, Follador A et al. Sequential, alternating and maintenance/consolidation chemotherapy in advanced non small cell lung cancer: a review of the literature. Oncologist 2007; 12: 451–64.
35. Shepherd FA. Maintenance chemotherapy in advanced non-small cell lung cancer. ХХI ICACT, Paris, 2010, 32 [abstract].
36. Ciuleanu T, Brodowicz T, Zielinski C et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomized, double-blind, phase 3 study. Lancet 2009; 374: 1432–40.

М.Б.Бычков, С.А.Большакова, Ю.М.Бычков

РОНЦ им. Н.Н.Блохина РАМН, ФГУ РНЦРР Росздрава, Москва